Gan & Lee Pharmaceuticals. (SHA:603087)

Market Cap	33.74B
Revenue (ttm)	3.47B
Net Income (ttm)	830.58M
Shares Out	598.96M
EPS (ttm)	1.41
PE Ratio	39.89
Forward PE	32.94
Dividend	1.50 (2.65%)
Ex-Dividend Date	Jun 11, 2025

Volume	10,994,626
Average Volume	13,205,215
Open	56.43
Previous Close	56.66
Day's Range	56.05 - 57.60
52-Week Range	37.63 - 57.94
Beta	1.61
RSI	72.25
Earnings Date	Aug 29, 2025

About SHA:603087

Gan & Lee Pharmaceuticals., a biopharmaceutical company, engages in the research, development, production, and sale of insulin analog active pharmaceutical ingredients (APIs) and injections in China. The company’s products include Basalin, an insulin glargine injection; Prandilin, an insulin lispro and lispro mix 75/25 injection; Prandilin 25, an insulin lispro injection; Rapilin, an insulin aspart injection; Rapilin 30, an insulin aspart 30 injection; and Similin 30, an insulin injection. It also offers GanleePen, an insulin injection device; ...

• Industry: Medical Instruments & Supplies
• Sector: Healthcare
• Founded: 1998
• Employees: 5,245
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 603087

Financial Performance

In 2024, SHA:603087's revenue was 3.05 billion, an increase of 16.77% compared to the previous year's 2.61 billion. Earnings were 614.66 million, an increase of 80.75%.